Some pharmacokinetic parameters of the trypanocidal drug homidium bromide in Friesian and Boran steers using an enzyme-linked immunosorbent assay (ELISA)

Pharmacokinetic studies on the trypanocidal drug homidium bromide using a c ompetitive enzyme immunoassay (detection limit 0.1 ng/mL) are reported for non-infected Friesian and Boran steers following treatment with homidium br omide at a dose of 1.0 mg/kg b.w. Following intravenous (i.v.) treatment of Friesian steers (n=5), the mean serum drug concentrations were 31.9+/-2.1 and 3.9+/-0.4 ng/mL at 1 and 24 h, respectively, The decline in serum drug concentration was tri-exponential with half-lives of 0.064 +/- 0.037 h for t(1/2 alpha), 7.17 +/- 1.87 h for t(1/2 beta) and 106.3 +/- 6.6 h for t(1/2 gamma), for distribution and elimination phases 1 and 2, respectively. Dru g was detectable in serum for 17 days following treatment. The mean residen ce time (MRT) was 63.4 +/- 7.5 h. Following intramuscular (i.m.) treatment of Friesian steers (n = 5), the drug concentration at 1 h after treatment w as 72.5 +/- 2.2 ng/mL. This declined to 9.8 +/- 1.8 ng/mL at 24 h, Low conc entrations of between 0.1 and 0.3 ng/mL remained in circulation for up to 9 0 days post-treatment. Following intramuscular treatment of Boran steers (n =5), the mean serum drug concentration at 1 h after treatment was 112.1 +/- 40.3 ng/mL. By 24 h after treatment, the concentration had fallen to 13.0 +/- 3.3 ng/mL, Thereafter, the serum drug concentration-versus-time profile and the pharmacokinetic parameters obtained following non-compartmental an alysis were similar to those obtained following intramuscular treatment of Friesian steers.